BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 37876923)

  • 1. Deciphering the role of HPV-mediated metabolic regulation in shaping the tumor microenvironment and its implications for immunotherapy in HNSCC.
    Gong X; Xiong J; Gong Y; Zhang J; Zhang J; Yang G; Chi H; Tian G
    Front Immunol; 2023; 14():1275270. PubMed ID: 37876923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tertiary Lymphoid Structure Raises Survival and Immunotherapy in HPV
    Li H; Zhu SW; Zhou JJ; Chen DR; Liu J; Wu ZZ; Wang WY; Zhang MJ; Sun ZJ
    J Dent Res; 2023 Jun; 102(6):678-688. PubMed ID: 36883630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune microenvironment of human papillomavirus-positive head and neck squamous cell carcinoma.
    Zhu D; He X; Li Y; Li G; Chen M
    Sci Prog; 2024; 107(1):368504241237888. PubMed ID: 38545800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioinformatic analysis identifies HPV-related tumor microenvironment remodeling prognostic biomarkers in head and neck squamous cell carcinoma.
    Zhou Q; Yuan O; Cui H; Hu T; Xiao GG; Wei J; Zhang H; Wu C
    Front Cell Infect Microbiol; 2022; 12():1007950. PubMed ID: 36425786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy Advances in Locally Advanced and Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma and Its Relationship With Human Papillomavirus.
    Wang H; Zhao Q; Zhang Y; Zhang Q; Zheng Z; Liu S; Liu Z; Meng L; Xin Y; Jiang X
    Front Immunol; 2021; 12():652054. PubMed ID: 34305889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma.
    Zhang J; Zhong X; Jiang H; Jiang H; Xie T; Tian Y; Li R; Wang B; Zhang J; Yuan Y
    Aging (Albany NY); 2020 Nov; 12(22):22509-22526. PubMed ID: 33216727
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive investigation into the influence of glycosylation on head and neck squamous cell carcinoma and development of a prognostic model for risk assessment and anticipating immunotherapy.
    Ma H; Xiong L; Zhao B; Hahan Z; Wei M; Shi H; Yang S; Ren Q
    Front Immunol; 2024; 15():1364082. PubMed ID: 38562924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
    Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
    Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The tumor microenvironment-relay station for prognosis and therapy response].
    Krupar R
    Pathologie (Heidelb); 2022 Aug; 43(Suppl 1):141-147. PubMed ID: 36414699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Programmed Death-1/Programmed Death-Ligand 1-Axis Blockade in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Stratified by Human Papillomavirus Status: A Systematic Review and Meta-Analysis.
    Xu Y; Zhu G; Maroun CA; Wu IXY; Huang D; Seiwert TY; Liu Y; Mandal R; Zhang X
    Front Immunol; 2021; 12():645170. PubMed ID: 33897693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HPV16 E5 Mediates Resistance to PD-L1 Blockade and Can Be Targeted with Rimantadine in Head and Neck Cancer.
    Miyauchi S; Sanders PD; Guram K; Kim SS; Paolini F; Venuti A; Cohen EEW; Gutkind JS; Califano JA; Sharabi AB
    Cancer Res; 2020 Feb; 80(4):732-746. PubMed ID: 31848196
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV and the Immune System in Head and Neck Cancers: Therapeutic Considerations.
    Grinnell M; Krishnan M; Ganti AK
    Oncology (Williston Park); 2020 Apr; 34(4):. PubMed ID: 32293695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor microenvironment: an evil nexus promoting aggressive head and neck squamous cell carcinoma and avenue for targeted therapy.
    Bhat AA; Yousuf P; Wani NA; Rizwan A; Chauhan SS; Siddiqi MA; Bedognetti D; El-Rifai W; Frenneaux MP; Batra SK; Haris M; Macha MA
    Signal Transduct Target Ther; 2021 Jan; 6(1):12. PubMed ID: 33436555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment.
    Ruffin AT; Li H; Vujanovic L; Zandberg DP; Ferris RL; Bruno TC
    Nat Rev Cancer; 2023 Mar; 23(3):173-188. PubMed ID: 36456755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Tumor-Specific Immune Landscape in HPV+ Head and Neck Cancer.
    Conarty JP; Wieland A
    Viruses; 2023 May; 15(6):. PubMed ID: 37376596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
    Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
    Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma.
    Seliger B; Massa C; Yang B; Bethmann D; Kappler M; Eckert AW; Wickenhauser C
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32987799
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intratumoral tertiary lymphoid structures promote patient survival and immunotherapy response in head neck squamous cell carcinoma.
    Liu Z; Meng X; Tang X; Zou W; He Y
    Cancer Immunol Immunother; 2023 Jun; 72(6):1505-1521. PubMed ID: 36481914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Modulation of Head and Neck Squamous Cell Carcinoma and the Tumor Microenvironment by Conventional Therapeutics.
    Miyauchi S; Kim SS; Pang J; Gold KA; Gutkind JS; Califano JA; Mell LK; Cohen EEW; Sharabi AB
    Clin Cancer Res; 2019 Jul; 25(14):4211-4223. PubMed ID: 30814108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The head and neck cancer genome in the era of immunotherapy.
    Wijetunga NA; Yu Y; Morris LG; Lee N; Riaz N
    Oral Oncol; 2021 Jan; 112():105040. PubMed ID: 33197752
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.